Donor Pooling as an Effective Method to Increase MSC EV Production Without Compromising Therapeutic Potential

Area of Science:

• Cell biology
• Immunology
• Biotechnology

Background:

• Mesenchymal stromal cell extracellular vesicles (MSC EVs) show promise for treating autoimmune diseases due to their immunomodulatory properties.
• Scaling up MSC EV production is crucial for therapeutic and research applications.
• Rheumatoid arthritis is a key target for MSC EV-based therapies.

Purpose of the Study:

• To investigate donor pooling as a method to enhance MSC EV production and therapeutic efficacy.
• To evaluate the impact of pooled MSC EVs on an inflammatory arthritis model.

Main Methods:

• Four human umbilical cord MSC (UC-MSC) donors were pooled to generate MSC EV enrichments.
• EV yield and characteristics were analyzed.
• The therapeutic efficacy of pooled UC-MSC EVs was assessed in an inflammatory arthritis model.

Main Results:

• Donor pooling significantly increased MSC EV yield, particle number, and EV-defining characteristics.
• Pooled UC-MSC EVs demonstrated superior therapeutic efficacy in alleviating arthritic pathophysiology compared to single-donor EVs and parental cells.
• Protein analysis suggested potential upregulation of protein transport mechanisms in pooled EVs.

Conclusions:

• Donor pooling is a simple and effective strategy to increase MSC EV production.
• This method can enhance MSC EV yield without compromising therapeutic efficacy for conditions like rheumatoid arthritis.
• Pooled MSC EVs represent a promising therapeutic approach for autoimmune diseases.